Preference of Genetic Polymorphism and Pharmacokinetics

Genetic polymorphism affects plasma concentration of antiretroviral therapy in HIV patients. The investigators investigate the prevalence of genetic polymorphism affecting efavirenz metabolism and the corresponding pharmacokinetics of different genotypes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV

Sex eligibility

All sexes

Study type

Observational

Primary location

The Chinese University of Hong Kong

Hong Kong, China

About this study

Eligible patients are invited to donate blood samples for pharmacokinetic study and genotype analysis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Southern Chinese HIV patients on efavirenz

Exclusion criteria

Refuse to sign consent, HIV patients not on efavirenz

Treatment and study plan

Primary outcomes

pharmacokinetics

Time frame: 24 hour

This includes plasma concentration of drugs in relation to time, in different genotypes

Secondary outcomes

genotypes frequency

Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Official study title

Preference of CYP450 2B6 516 G>T Polymorphism and Pharmacokinetics of Plasma Efavirenz in A Group of HIV Infected Southern Chinese

Important dates

Study start: 2008
Primary completion: 2009
Study completion: 2010
First posted: Aug 7, 2012
Registry last updated: Aug 7, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed